Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Buteau

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.
European Urology Open Science|July 13, 2023
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate BiopsyBrian D Kelly, Gideon Ptasznik, Matthew J Roberts, et al.
BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Journal of Urology|May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate CancerLouise Emmett, Nathan Papa, Thomas A Hope, et al.
European Urology|September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre StudyLouise Emmett, James Buteau, Nathan Papa, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Urology Oncology|April 7, 2024
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialAndrei Gafita, Andrew J Martin, Louise Emmett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.
European Urology Open Science|July 13, 2023
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate BiopsyBrian D Kelly, Gideon Ptasznik, Matthew J Roberts, et al.
BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Journal of Urology|May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate CancerLouise Emmett, Nathan Papa, Thomas A Hope, et al.
European Urology|September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre StudyLouise Emmett, James Buteau, Nathan Papa, et al.
Pageof 2